Can Amazon change how the PBM and pharmacy worlds operate?
https://medcitynews.com/2021/07/cvs-offers-amazon-legal-lessons-as-it-enters-the-discount-scrip-fray/
All in on amyloid, Acumen Pharma’s IPO raises $160M for Alzheimer’s drug R&D
https://medcitynews.com/2021/07/all-in-on-amyloid-acumen-pharmas-ipo-raises-160m-for-alzheimers-drug-rd/
Don’t be fooled by a full waiting room—ambulatory care offices are being left behind
https://medcitynews.com/2021/07/dont-be-fooled-by-a-full-waiting-room-ambulatory-care-offices-are-being-left-behind/
Drug R&D is broken; how to put the tech in biotech
https://medcitynews.com/2021/07/drug-r-how-to-put-the-tech-in-biotech/
Apellis taps Beam’s base-editing tech to broaden autoimmune disease scope
https://medcitynews.com/2021/06/apellis-taps-beams-base-editing-tech-to-broaden-autoimmune-disease-scope/
Texas Children’s, PeriGen bring AI-powered maternal-fetal monitoring system to Malawi
https://medcitynews.com/2021/06/texas-childrens-perigen-bring-ai-powered-maternal-fetal-monitoring-system-to-malawi/
Dexcom’s CEO claims company has a ‘compelling’ case for broader CGM use
https://medcitynews.com/2021/06/dexcoms-ceo-claims-company-has-a-compelling-case-for-broader-cgm-use/
Why Google is focusing its consumer health efforts on Fitbit
https://medcitynews.com/2021/06/why-google-is-focusing-its-consumer-health-efforts-on-fitbit/
Telehealth boom expected to flatten, according to new report
https://medcitynews.com/2021/06/telehealth-boom-expected-to-flatten-according-to-new-report/
FDA rejection of rare disease drug leads Orphazyme to cut two thirds of staff
https://medcitynews.com/2021/06/fda-rejection-of-rare-disease-drug-leads-orphazyme-to-cut-two-thirds-of-staff/
